Literature DB >> 30045065

Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.

Alena Skálová1, Tomas Vanecek1,2, Emmanuelle Uro-Coste3,4, Justin A Bishop5, Ilan Weinreb6, Lester D R Thompson7, Stefano de Sanctis8, Marco Schiavo-Lena9, Jan Laco10, Cécile Badoual11, Thalita Santana Conceiçao12, Nikola Ptáková2, Martina Baněčkova1, Marketa Miesbauerová1, Michal Michal1.   

Abstract

Intraductal carcinoma (IC) is the new World Health Organization designation for tumors previously called "low-grade cribriform cystadenocarcinoma" and "low-grade salivary duct carcinoma." The relationship of IC to salivary duct carcinoma is controversial, but they now are considered to be distinct entities. IC is a rare low-grade malignant salivary gland neoplasm with features similar to mammary atypical ductal hyperplasia or ductal carcinoma in situ, that shows diffuse S100 protein and mammaglobin positivity and is only partially defined genetically. (Mammary analogue) secretory carcinoma harboring ETV6-NTRK3, and in rare cases ETV6-RET fusion, shares histomorphologic and immunophenotypical features with IC. Recently, RET rearrangements and NCOA4-RET have been described in IC, suggesting a partial genetic overlap with mammary analogue secretory carcinoma. Here, we genetically characterize the largest cohort of IC to date to further explore this relationship. Seventeen cases of IC were analyzed by next-generation sequencing using the FusionPlex Solid Tumor kit (ArcherDX). Identified fusions were confirmed using fluorescence in situ hybridization break apart and, in some cases, fusion probes, and a reverse transcription polymerase chain reaction designed specifically to the detected breakpoints. All analyzed cases were known to be negative for ETV6 rearrangement by fluorescence in situ hybridization and for ETV6-NTRK3 fusion by reverse transcription polymerase chain reaction. Next-generation sequencing analysis detected a NCOA4-RET fusion transcript joining exon 7 or 8 of NCOA4 gene and exon 12 of RET gene in 6 cases of intercalated duct type IC; and a novel TRIM27-RET fusion transcript between exons 3 and 12 in 2 cases of salivary gland tumors displaying histologic and immunohistochemical features typical of apocrine IC. A total of 47% of IC harbored a fusion involving RET. In conclusion, we have confirmed the presence of NCOA4-RET as the dominant fusion in intercalated duct type IC. A novel finding in our study has been a discovery of a subset of IC patients with apocrine variant IC harboring a novel TRIM27-RET.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30045065     DOI: 10.1097/PAS.0000000000001133

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor.

Authors:  Justin A Bishop; Jeffrey Gagan; Jeffrey F Krane; Vickie Y Jo
Journal:  Head Neck Pathol       Date:  2020-01-27

2.  Salivary Intraductal Carcinoma Arising within Intraparotid Lymph Node: A Report of 4 Cases with Identification of a Novel STRN-ALK Fusion.

Authors:  Lisa M Rooper; Lester D R Thompson; Jeffrey Gagan; Bahram R Oliai; Ilan Weinreb; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2020-07-13

3.  Biphenotypic Branchioma: A Better Name Than Ectopic Hamartomatous Thymoma for a Neoplasm with HRAS Mutation.

Authors:  Lester D R Thompson; Jeffrey Gagan; Antoine Washington; Rodney T Miller; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2020-02-05

Review 4.  Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.

Authors:  Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao
Journal:  Cancer Cytopathol       Date:  2020-05-18       Impact factor: 5.284

5.  HMGA2 Immunoexpression is frequent in salivary gland pleomorphic adenoma: immunohistochemical and molecular analyses of PLAG1 and HMGA2 in 25 cases.

Authors:  Adepitan A Owosho; Olufunlola M Adesina; Oluwole Odujoko; Hezekiah Akinyemi; Akinwumi Komolafe; Simon Tadros; Robert Bauer; Kurt F Summersgill
Journal:  Int J Clin Exp Pathol       Date:  2022-02-15

6.  Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.

Authors:  Juan C Hernandez-Prera; Daryoush Saeed-Vafa; Amin Heidarian; Kathleen Gewandter; Kristen Otto; Bruce M Wenig
Journal:  Head Neck Pathol       Date:  2021-08-19

7.  Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions.

Authors:  Cristina R Antonescu; Brendan C Dickson; David Swanson; Lei Zhang; Yun-Shao Sung; Yu-Chien Kao; Wei-Chin Chang; Leili Ran; Alberto Pappo; Armita Bahrami; Ping Chi; Christopher D Fletcher
Journal:  Am J Surg Pathol       Date:  2019-10       Impact factor: 6.394

8.  Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33-RET fusions and BRAF V600E mutations.

Authors:  Justin A Bishop; Masato Nakaguro; Rumeal D Whaley; Kanako Ogura; Hiroshi Imai; Israa Laklouk; William C Faquin; Peter M Sadow; Jeffrey Gagan; Toshitaka Nagao
Journal:  Histopathology       Date:  2021-03-31       Impact factor: 5.087

9.  MYB-NFIB Translocation by FISH in Adenoid Cystic Carcinoma of the Head and Neck in Nigerian Patients: A Preliminary Report.

Authors:  Adepitan A Owosho; Olufunlola M Adesina; Oluwole Odujoko; Olujide O Soyele; Akinwumi Komolafe; Robert Bauer; Kallie Holte; Kurt F Summersgill
Journal:  Head Neck Pathol       Date:  2020-08-28

10.  Targeted RNA sequencing in the routine clinical detection of fusion genes in salivary gland tumors.

Authors:  Justin Bubola; Christina M MacMillan; Elizabeth G Demicco; Rose A Chami; Catherine T-S Chung; Iona Leong; Paula Marrano; Zeynep Onkal; David Swanson; Brandon M Veremis; Ilan Weinreb; Lei Zhang; Cristina R Antonescu; Brendan C Dickson
Journal:  Genes Chromosomes Cancer       Date:  2021-07-08       Impact factor: 4.263

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.